Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of n-Butylidenephthalide for making medicines treating liver injuries and improving liver functions and medical composition

A technology of butenylbenzene and liver damage, which is applied in the field of the use and pharmaceutical composition of n-butenylphthalide in the manufacture of medicines for treating liver damage and improving liver function, and can solve the problem of butenylbenzene that no one has proposed. Problems such as phthalides and no evidence

Active Publication Date: 2013-06-26
DONGHUA UNIV
View PDF5 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, no one has yet proposed that butenylphthalide has a therapeutic effect on liver damage including liver inflammation, cirrhosis, and liver fibrosis. At the same time, there is no evidence that butenylphthalide has a therapeutic effect on liver damage. It also has the effect of reversing the liver function recovery of liver damage caused by the pathological process of liver fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of n-Butylidenephthalide for making medicines treating liver injuries and improving liver functions and medical composition
  • Use of n-Butylidenephthalide for making medicines treating liver injuries and improving liver functions and medical composition
  • Use of n-Butylidenephthalide for making medicines treating liver injuries and improving liver functions and medical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0030] The concepts described herein will be further illustrated by the following examples, which do not limit the scope of the invention described in the claims.

[0031] The present invention proves its feasibility with rat chronic liver injury model.

[0032] Establishment of chronic liver fibrosis model and assessment of liver function

[0033] In this example, 102 eight-week-old Wistar rats obtained from LASCO Company (Taiwan) were used. All procedures followed ethical guidelines and were approved by the Animal Care and Use Committee of the Research Institution of National Dong Hwa University, Taiwan.

[0034] In order to establish a chronic liver injury model in rats, 78 adult male Wistar rats (320 ± 20 g) were intraperitoneally injected with 5 ml of thioacetamide (TAA (Sigma-Aldrich)) every three days for 8 weeks. as a fibrosis model group. The remaining 24 rats were used as the normal group (Normal group), and normal saline was used instead of TAA. At the end of ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a medical composition. The medical composition comprises n-Butylidenephthalide (Type Z) illustrated by formula (I) and used for effective dose treatment, type E or the mixture of type E and type Z, or medically acceptable salt or ester and a medically acceptable carrier. The medical composition in the invention can be used for treating liver injuries such as liver fibrosis, liver cirrhosis and liver abscess, and / or improving liver functions.

Description

technical field [0001] The invention relates to a pharmaceutical composition containing n-butenylphthalide for treating liver damage, and n-butenylphthalide (n-butylidenephthalide) is used in the preparation of liver damage such as liver fibrosis, cirrhosis or liver inflammation. Uses in medicines, and medicines for improving liver function. Background technique [0002] Liver disease is a common disease among Chinese. At present, there are 350 million people in the world infected with chronic hepatitis B. The carriers of hepatitis B in Taiwan are about 3 to 4 million (15% to 20%), and the carriers of hepatitis C are about 30%. ~400,000 people (2%), chronic liver disease causes about 6,000 deaths per year, and 5,000 deaths from liver cancer. The global hepatitis market and demand are still expanding rapidly. In the 1930s, about 90% of prescription drugs or patented drugs belonged to plants. However, with the advancement of science and technology, synthetic drugs have gradua...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/365A61P1/16
Inventor 邱紫文韩鸿志林欣荣
Owner DONGHUA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com